Trisalus Life Sciences Stock Earnings Reports

TriSalus reported Q1 2026 revenue of $8.9 million (vs. $9.2M prior year) and an adjusted EBITDA loss of ~$5.8 million. Management attributes the modest revenue shortfall to a deliberate and large commercial expansion (re‑territoring, onboarding and new leadership) that disrupted ~40% of territories in the quarter; ~60% of territories performed in line with expectations. The company raised capital in Q1 to fund the expansion, ending March 31 with $56.6 million in cash. Gross margin remains strong (~86%). Management lowered full‑year 2026 revenue guidance to $54–57 million, primarily because (1) the commercial build-out reduced near‑term sales and (2) FDA clearance of TriNav Advance (microcatheter‑compatible device) is delayed ~5 months beyond the 30‑day MDUFA target, pushing a potential Advance revenue contribution beyond the company’s near‑term forecast. The company announced publication of the largest real‑world evidence (RWE) study of its PEDD platform (603 PEDD patients vs >16,000 non‑PEDD controls) showing statistically better clinical outcomes, substantially lower post‑procedure complications and ~ $7,700 per patient downstream cost avoidance. Management emphasized multiple ongoing and upcoming prospective and retrospective studies across liver and new indications (uterine, thyroid, genicular embolization) and reiterated plans to deliver a consolidated nelitolimod PERIO Phase I readout in early H2 2026. Management expects rep ramp time of ~6–9 months, anticipates marginal sequential Q2 improvement and more meaningful contribution in H2 as new reps reach productivity and (subject to clearance) new product launches occur. Key takeaways for investors: strong gross margins and cash runway to execute the commercial build, meaningful peer‑reviewed RWE that may accelerate institutional adoption and payer conversations, conservatively reset near‑term revenue guidance due to execution timing and an FDA review delay, and multiple clinical catalysts across 2026 (PEDD publications, trial initiations, nelitolimod consolidated readout, potential TriNav Advance launch).